Reviews
1 July 2025
Early Access
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
159
Views
117
Downloads
Authors
Mesenchymal stem cell (MSC) therapy holds promise for treating immune-mediated inflammatory skin diseases (IMIDs), particularly when conventional therapies are ineffective. Encouraged by their immunomodulatory capabilities and potential for disease modification, different clinical trials are investigating the efficacy and safety of MSCs in single IMIDs. This review aims to summarize the application of MSCs in IMIDs and explore their future clinical potential. We reviewed published studies from January 2016 to January 2024 on MSC treatment for IMIDs. We retrieved 18 clinical trials and 5 observational studies, encompassing 609 patients with psoriasis, atopic dermatitis (AD), chronic spontaneous urticaria (CSU), alopecia areata (AA), systemic sclerosis (SSc), and systemic lupus erythematosus (SLE). Improvements or complete remission were observed in up to 100% of cases for AA, SSc, and SLE, though complete remission rates were less frequent than improvement rates, ranging from 0% in AD to 50% in CSU. Adverse events (AEs) were generally mild; moderate-to-severe AEs were uncommon (4% in psoriasis, 2.6% in SLE, and 0.7% in SSc), and deaths from all causes were rare (6 patients with SSc and 15 patients with SLE). In conclusion, MSC therapy shows promising results in terms of at least partial clinical improvement for most IMIDs. Its effect is achievable after a single or a few administrations, with no significant toxicity. MSCs may fulfill an unmet need for patients unresponsive to conventional immunomodulating agents. However, most evidence still comes from clinical trials with heterogeneous designs and endpoints. Future larger controlled trials are needed to better elucidate their role in refractory IMIDs.
Altmetrics
Downloads
Download data is not yet available.
Citations
1. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-7. DOI: https://doi.org/10.1080/14653240600855905
2. Berebichez-Fridman R, Montero-Olvera PR. Sources and Clinical Applications of Mesenchymal Stem Cells: State-of-the-art review. Sultan Qaboos Univ Med J 2018;18:e264-77. DOI: https://doi.org/10.18295/squmj.2018.18.03.002
3. Gao F, Chiu SM, Motan D, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis 2016;7:e2062. DOI: https://doi.org/10.1038/cddis.2015.327
4. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 2007;25:2648-59. DOI: https://doi.org/10.1634/stemcells.2007-0226
5. Falanga V, Iwamoto S, Chartier M, et al. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng 2007;13:1299-312. DOI: https://doi.org/10.1089/ten.2006.0278
6. Fu X, Liu G, Halim A, et al. Mesenchymal Stem Cell Migration and Tissue Repair. Cells 2019;8:784. DOI: https://doi.org/10.3390/cells8080784
7. Galipeau J, Sensébé L. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell 2018;22:824-33. DOI: https://doi.org/10.1016/j.stem.2018.05.004
8. Squillaro T, Peluso G, Galderisi U. Clinical Trials With Mesenchymal Stem Cells: An Update. Cell Transplant 2016;25:829-48. DOI: https://doi.org/10.3727/096368915X689622
9. Galleu A, Riffo-Vasquez Y, Trento C, et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Transl Med 2017;9:eaam7828. DOI: https://doi.org/10.1126/scitranslmed.aam7828
10. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 2012;7:e47559. DOI: https://doi.org/10.1371/journal.pone.0047559
11. Wuchter P, Bieback K, Schrezenmeier H, et al. Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy 2015;17:128-39. DOI: https://doi.org/10.1016/j.jcyt.2014.04.002
12. Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006;20:661-9. DOI: https://doi.org/10.1096/fj.05-5211com
13. Badillo AT, Beggs KJ, Javazon EH, et al. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response. Biol Blood Marrow Transplant 2007;13:412-22. DOI: https://doi.org/10.1016/j.bbmt.2006.12.447
14. Ghannam S, Pène J, Moquet-Torcy G, et al. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 2010;185:302-12. DOI: https://doi.org/10.4049/jimmunol.0902007
15. Griffin MD, Ritter T, Mahon BP. Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther 2010;21:1641-55. DOI: https://doi.org/10.1089/hum.2010.156
16. Gu LH, Zhang TT, Li Y, et al. Immunogenicity of allogeneic mesenchymal stem cells transplanted via different routes in diabetic rats. Cell Mol Immunol 2015;12:444-55. DOI: https://doi.org/10.1038/cmi.2014.70
17. Kim KH, Blasco-Morente G, Cuende N, Arias-Santiago S. Mesenchymal stromal cells: properties and role in management of cutaneous diseases. J Eur Acad Dermatol Venereol 2017;31:414-23. DOI: https://doi.org/10.1111/jdv.13934
18. Yao D, Ye S, He Z, et al. Adipose-derived mesenchymal stem cells (AD-MSCs) in the treatment for psoriasis: results of a single-arm pilot trial. Ann Transl Med 2021;9:1653. DOI: https://doi.org/10.21037/atm-21-5028
19. Cheng L, Wang S, Peng C, et al. Human umbilical cord mesenchymal stem cells for psoriasis: a phase 1/2a, single-arm study. Signal Transduct Target Ther 2022;7:263. DOI: https://doi.org/10.1038/s41392-022-01059-y
20. Kim HS, Lee JH, Roh KH, et al. Clinical Trial of Human Umbilical Cord Blood-Derived Stem Cells for the Treatment of Moderate-to-Severe Atopic Dermatitis: Phase I/IIa Studies. Stem Cells 2017;35:248-55. DOI: https://doi.org/10.1002/stem.2401
21. Shin HT, Lee SH, Yoon HS, et al. Long-term efficacy and safety of intravenous injection of clonal mesenchymal stem cells derived from bone marrow in five adults with moderate to severe atopic dermatitis. J Dermatol 2021;48:1236-42. DOI: https://doi.org/10.1111/1346-8138.15928
22. Özgül Özdemir RB, Özdemir AT, Kırmaz C, et al. Mesenchymal Stem Cells: a Potential Treatment Approach for Refractory Chronic Spontaneous Urticaria. Stem Cell Rev Rep 2021;17:911-22. DOI: https://doi.org/10.1007/s12015-020-10059-w
23. Elmaadawi IH, Mohamed BM, Ibrahim ZAS, et al. Stem cell therapy as a novel therapeutic intervention for resistant cases of alopecia areata and androgenetic alopecia. J Dermatolog Treat 2018;29:431-40. DOI: https://doi.org/10.1080/09546634.2016.1227419
24. Czarnecka A, Odziomek A, Murzyn M, et al. Wharton’s jelly-derived mesenchymal stem cells in the treatment of four patients with alopecia areata. Adv Clin Exp Med 2021;30:211-8. DOI: https://doi.org/10.17219/acem/132069
25. Lee SB, Shin HT, Byun JW, et al. Clinical efficacy of adipocyte-derived stem cells conditioned media combined with micro-injury in refractory patch of alopecia areata. Arch Dermatol Res 2022;314:527-32. DOI: https://doi.org/10.1007/s00403-021-02252-9
26. Zhang H, Liang J, Tang X, et al. Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis. Arthritis Res Ther 2017;19:165. DOI: https://doi.org/10.1186/s13075-017-1373-2
27. Blezien O, D’Andrea F, Nicoletti GF, Ferraro GA. Effects of Fat Grafting Containing Stem Cells in Microstomia and Microcheilia Derived from Systemic Sclerosis. Aesthetic Plast Surg 2017;41:839-44. DOI: https://doi.org/10.1007/s00266-017-0904-1
28. Virzì F, Bianca P, Giammona A, et al. Combined platelet-rich plasma and lipofilling treatment provides great improvement in facial skin-induced lesion regeneration for scleroderma patients. Stem Cell Res Ther 2017;8:236. DOI: https://doi.org/10.1186/s13287-017-0690-3
29. Liang J, Zhang H, Kong W, et al. Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study. Stem Cell Res Ther 2018;9:312. DOI: https://doi.org/10.1186/s13287-018-1053-4
30. Almadori A, Griffin M, Ryan CM, et al. Stem cell enriched lipotransfer reverses the effects of fibrosis in systemic sclerosis. PLoS One 2019;14:e0218068. DOI: https://doi.org/10.1371/journal.pone.0218068
31. Shoji K, Yanishi K, Yoshimi R, et al. Impact of Therapeutic Angiogenesis Using Autologous Bone Marrow-Derived Mononuclear Cells Implantation in Critical Limb Ischemia With Scleroderma - Subanalysis of the Long-Term Clinical Outcomes Survey. Circ J 2019;83:662-71. DOI: https://doi.org/10.1253/circj.CJ-18-1044
32. Del Papa N, Di Luca G, Andracco R, et al. Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study. Arthritis Res Ther 2019;21:7. DOI: https://doi.org/10.1186/s13075-018-1792-8
33. Park Y, Lee YJ, Koh JH, et al. Clinical Efficacy and Safety of Injection of Stromal Vascular Fraction Derived from Autologous Adipose Tissues in Systemic Sclerosis Patients with Hand Disability: A Proof-Of-Concept Trial. J Clin Med 2020;9:3023. DOI: https://doi.org/10.3390/jcm9093023
34. Wang C, Long X, Si L, et al. A pilot study on ex vivo expanded autologous adipose-derived stem cells of improving fat retention in localized scleroderma patients. Stem Cells Transl Med 2021;10:1148-56. DOI: https://doi.org/10.1002/sctm.20-0419
35. Wang D, Niu L, Feng X, et al. Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study. Clin Exp Med 2017;17:333-40. DOI: https://doi.org/10.1007/s10238-016-0427-0
36. Wang D, Wang S, Huang S, et al. Serum IFN-γ Predicts the Therapeutic Effect of Mesenchymal Stem Cells Transplantation in Systemic Lupus Erythematosus Patients. Stem Cells Transl Med 2017;6:1777-85. DOI: https://doi.org/10.1002/sctm.17-0002
37. Barbado J, Tabera S, Sánchez A, García-Sancho J. Therapeutic potential of allogeneic mesenchymal stromal cells transplantation for lupus nephritis. Lupus 2018;27:2161-5. DOI: https://doi.org/10.1177/0961203318804922
38. Wen L, Labopin M, Badoglio M, et al. Prognostic Factors for Clinical Response in Systemic Lupus Erythematosus Patients Treated by Allogeneic Mesenchymal Stem Cells. Stem Cells Int 2019;2019:7061408. DOI: https://doi.org/10.1155/2019/7061408
39. Kamen DL, Wallace C, Li Z, et al. Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE. Lupus Sci Med 2022;9:e000704. DOI: https://doi.org/10.1136/lupus-2022-000704
How to Cite
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review. (2025). Dermatology Reports. https://doi.org/10.4081/dr.2025.10112
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
